Tanaka H, Fukuda M, Inoguchi S, Tsuji Y
Department of Pediatrics, School of Medicine, Nagasaki University.
Jpn J Antibiot. 1990 Mar;43(3):524-7.
Pharmacokinetics and clinical evaluation of aztreonam (AZT) in the neonates and premature infants were studied with the following results: 1. Serum concentrations of AZT in 60 minutes intravenous drip infusion of AZT 20 mg/kg to 6 cases of neonates with 2 to 22 days of age were 45.5 +/- 0.87 micrograms/ml immediately after the completion of intravenous drip infusion, 37.8 +/- 1.62 micrograms/ml 1 hour after, 31.2 +/- 1.92 micrograms/ml 2 hours after and 19.7 +/- 2.36 micrograms/ml 4 hours after, respectively. Serum half-life was 3.61 +/- 0.53 hours on the average. 2. Urinary excretion rate 6 hours after intravenous drip infusion was 26.4 +/- 6.86% on the average. 3. Clinical evaluation was given to 1 sepsis case of 7-days of age and it was effective. There was no abnormal clinical or laboratory finding considered to be associated with AZT.
对氨曲南(AZT)在新生儿和早产儿中的药代动力学及临床评价进行了研究,结果如下:1. 对6例年龄在2至22天的新生儿静脉滴注20mg/kg氨曲南,滴注结束后即刻血清氨曲南浓度为45.5±0.87μg/ml,1小时后为37.8±1.62μg/ml,2小时后为31.2±1.92μg/ml,4小时后为19.7±2.36μg/ml。血清半衰期平均为3.61±0.53小时。2. 静脉滴注6小时后的尿排泄率平均为26.4±6.86%。3. 对1例7日龄败血症患儿进行了临床评价,结果有效。未发现与氨曲南相关的异常临床或实验室检查结果。